EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance

Stefano Fogli, Beatrice Polini, Marzia Del Re, Iacopo Petrini, Antonio Passaro, Stefania Crucitta, Eleonora Rofi, Romano Danesi

Research output: Contribution to journalReview articlepeer-review


The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles. Furthermore, acquired drug resistance may limit the therapeutic potential of EGFR-TKIs and the choice of the best treatment strategy after first-line treatment failure is still debated. This review article is aimed at describing the pharmacological properties of EGFR-TKIs and the current treatment options for NSCLC patients who develop acquired resistance. This information might be useful to design new rational and more effective pharmacological strategies in patients with EGFR-mutant NSCLC.

Original languageEnglish
Pages (from-to)727-740
Number of pages14
Issue number8
Publication statusPublished - Jan 1 2018


  • drug resistance
  • non-small-cell lung cancer
  • pharmacology

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance'. Together they form a unique fingerprint.

Cite this